Trial · NCT05795062
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | Apixaban | 11966 | Participants | ||
| Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | Warfarin | 1979 | Participants | ||
| Mean Number of Persistent Days | Apixaban | 233.5 | Standard Deviation 302.9 | Days | |
| Mean Number of Persistent Days | Warfarin | 242.6 | Standard Deviation 304.4 | Days | |
| Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | Apixaban | 50.5 | Percentage of Participants | ||
| Percentage of Participants Who Discontinued Index Treatment at 6 Months Post-Discharge Index Date | Warfarin | 52.2 | Percentage of Participants | ||
| Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | Apixaban | 72.9 | Percentage of Participants | ||
| Percentage of Participants Who Discontinued Index Treatment at 12 Months Post-Discharge Index Date | Warfarin | 75.2 | Percentage of Participants | ||
| Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | Apixaban | 6.0 | Percentage of Participants | ||
| Percentage of Participants Who Switched From Index Treatment at 6 Months Post-Discharge Index Date | Warfarin | 20.9 | Percentage of Participants | ||
| Percentage of Participants Who Switched From Index Treatment at Month 12 Post-Discharge Index Date | Apixaban | 7.1 | Percentage of Participants | ||
| Percentage of Participants Who Switched From Index Treatment at Month 12 Post-Discharge Index Date | Warfarin | 24.3 | Percentage of Participants | ||
| Median Time to Discontinuation From the Index Treatment | Apixaban | 5.97 | Inter-Quartile Range 5.83 to 6.07 | Months | |
| Median Time to Discontinuation From the Index Treatment | Warfarin | 5.67 | Inter-Quartile Range 5.17 to 6.03 | Months | |
| Median Time to Switch From the Index Treatment | Apixaban | NA | 95% Confidence Interval NA to NA | Months | |
| Median Time to Switch From the Index Treatment | Warfarin | NA | 95% Confidence Interval NA to NA | Months | |
| Incidence Rate of Recurrent VTE Events | Apixaban | 1.2 | Events per 100 participant-years | ||
| Incidence Rate of Recurrent VTE Events | Warfarin | 2.5 | Events per 100 participant-years | ||
| Median Time to Recurrent VTE | Apixaban | NA | Full Range NA to NA | Months | |
| Median Time to Recurrent VTE | Warfarin | NA | Full Range NA to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05795062/results